J Korean Med Sci.
2018 Dec;33(51):e325. 10.3346/jkms.2018.33.e325.
Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
- Kim MS
- Chung HS
- Hwang EC
- Jung SI
- Kwon DD
- Hwang JE
- Bae WK
- Park JY
- Jeong CW
- Kwak C
- Song C
- Seo SI
- Byun SS
- Hong SH
- Chung J
- Affiliations
-
- 1Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. urohwang@gmail.com
- 2Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. juneul2@gmail.com
- 3Department of Urology, Korea University Ansan Hospital, Ansan, Korea.
- 4Department of Urology, Seoul National University Hospital, Seoul, Korea.
- 5Department of Urology, Asan Medical Center, Seoul, Korea.
- 6Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 7Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
- 8Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.
- 9Department of Urology, National Cancer Center, Goyang, Korea.
- KMID: 2428635
- DOI: http://doi.org/10.3346/jkms.2018.33.e325
Abstract
- BACKGROUND
To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice.
METHODS
Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS.
RESULTS
The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS.
CONCLUSION
Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
- Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
- Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
- A Case of Sunitinib-Induced Destructive Thyroiditis
- A case of thyrotoxicosis after sunitinib treatment
